Join us at ESHRE
Booth C006. 29 June -2 July 2025 - Paris, France
We are very pleased to welcome you to the Vitrolife Group booth (Booth C006) at ESHRE, 29th of June – 2nd of July in Paris, France. Come join us and explore our full range of innovative portfolio of products & services. Listen to inspiring presentations in the Academy Studio and experience hands-on live demonstration of our Sense needle, eWitness and the new Ultra-fast warming media.
Vitrolife Group Academy Studio
Join our Academy Studio live at ESHRE for interactive and inspirational sessions and demonstrations.
Can’t make it to ESHRE in Paris? No problem! We’ll be live-streaming all our Monday Academy Studio presentations on our social media channels. We’ll be live-streaming all our Monday Academy Studio presentations on our social media channels. We will also record Tuesday's product demonstrations and share them later on both our social media channels and website - so you will not miss a thing.
Visit our LinkedIn channels and join in!
Download academy programmeDiscover our News
Coming Soon: EmbryoScope x eWitness Integration
Come and visit us at the booth to discover how our state of art EmbyroScope feature update can seamlessly integrate with your in-clinic systems — making your workflow smoother, smarter, and more connected.
Gain 1 Hour Every Single Day with Ultra RapidWarm™ Blast
Ultra RapidWarm™ Blast helps embryologists save up to one hour of work time per day. It delivers a clinically proven one-step protocol that warms blastocysts in just minutes—with comparable survival and pregnancy rates.
Ultra RapidWarm Blast is used for warming of vitrified human blastocyst-stage embryos. The medium contains 0.25 M sucrose, and is supplied in four 5 ml bottles. Each bottle can be used for two weeks after first opening, if aseptic technique is used and time outside the refrigerator is minimised.
The new product innovation is a game-changing procedure:
- Save 8-11 minutes per blastocyst
- Maintain safety and efficacy
- More robust protocol with reduced handling risk
- Streamlined workflow with increased flexibility
- Easy-to-train protocol
The low sucrose level in Ultra RapidWarm Blast during warming reduces osmotic shock. Studies have shown that low sucrose solutions result in faster re-expansion and higher hatching rates compared to warming in higher sucrose solutions. Furthermore, using a low sucrose solution may result in a more standardised warming protocol with less risk of loosing visual control and exceeding the time in solution.
Download ltra RapidWarm™ Blast brochureEmbryoMap SNP elevates your CNV analysis with the addition of SNP detection
The EmbryoMap SNP reagent integrates seamlessly into the existing EmbryoMap workflow. .
This new solution delivers CNV analysis with ploidy and exogenous DNA contamination detection..
Come and talk to us at the booth to find out more about the:
- Single Reagent
- Single Workflow
- Single Sequencing Run
eWitness optimises lab workflow and enhance security with reliable insights
The IVF treatment process has been in full development in recent years. There is a continuous addition of new features and improved technologies, making operations more and more complex. Securing these process flows is becoming increasingly important.
✓ Automation of the entire workflow
✓ Monitoring of all actions
✓ Barcodes and RFID on printable labels
✓ Electronic double-checking
eWitness contributes greatly to managing the quality of IVF treatment programmes. It prevents critical errors such as mixups of sperm, eggs, and/or embryos. eWitness provides clarity to the user in every step of the process.
Download eWitness brochureEMMA and ALICE just got smarter!
Powered by the most scientific and clinical support, EMMA&ALICE is the most widely used endometrial microbiome test worldwide and the only commercially available test that delivers an endometrial-specific bacterial panel.
Leveraging our experience, we continue to deliver advancements to the analysis and optimization of the endometrial microbiome.
We introduce our newest update that includes:
- A fully enhanced view of the Lactobacillus population, allowing for a better understanding of the endometrium’s ability to defend against the colonization of pathogenic bacteria.
- Simplified and easier to interpret Lactobacillus results enabling faster decision making for a patient’s personalized treatment plan.
- The most up-to-date reporting methodology, backed by prospective trials, to deliver the most optimal patient outcomes (Moreno et al., 2022).
ERA is more than a test – it’s a solution backed by science and trusted by fertility experts around the world
The Scientific Truth About ERA: Latest Evidence
We want to bring your attention to the latest independent research, including a groundbreaking randomized controlled trial (RCT) by Barbakadze et al. (2024), which reinforces the effectiveness of ERA in RIF patients. Additional prospective and retrospective studies, case reports, and major meta-analyses (Amin et al., 2022; Jia et al., 2024; Glujovsky et al., 2023, and many more) further validate the clinical relevance of the ERA test.
Explore more on ERA Insight HubGet in touch
Don't hesitate to contact us if you have any questions or want more information about our new products.
Fill out the form below and we'll get back to you as soon as we can.